enGene Q1 net loss $10.7M; CEO to resign; $200M PIPE extends cash into 2027

enGene Therapeutics Inc.

2024-Q1 EPS reported $0.46

Net loss $10.7M ($0.46/share) vs $8.6M ($13.29/share) YoY; operating expenses $10.8M vs $4.6M.
Completed $200M oversubscribed PIPE (20M shares at $10, 31% premium); net proceeds $187.5M.
Cash $85.6M as of Jan 31; with PIPE proceeds, expects runway into 2027.
CEO Jason Hanson to resign upon appointment of successor; Board conducting search.
Pivotal Phase 2 LEGEND study for EG-70 in NMIBC on track; interim data mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

enGene Therapeutics Inc. reported first quarter ended January 31, 2024 results: net income net loss attributable to common shareholders was $10.7 million, or $0.46 per share.

Period: first quarter ended January 31, 2024
Net income: net loss attributable to common shareholders was $10.7 million, or $0.46 per share
Result: reported results

Exact text from the filing

enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the first quarter ended January 31, 2024.

View on SEC.gov

Browse all earnings releases →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-029396

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.